Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth
نویسندگان
چکیده
منابع مشابه
The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
Purpose The potential effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on the weight of girls with central precocious puberty (CPP) remains a controversy. We investigated anthropometric changes during and after GnRHa treatment among girls with CPP. Methods This retrospective study evaluated data from 127 girls with CPP who received GnRHa treatment for ≥2 years. Height, weigh...
متن کاملTREATMENT OF PRECOCIOUS PUBERTY BY A LONG-ACTING GONADOTROPIN-RELEASING HORMONE ANALOGUE IN CHILDREN
The GnRH analogue has been shown to be effective in the treatment of precocious puberty when given as a daily subcutaneous injection. We studied the effectiveness of a long-acting GnRH analogue, Triptoreline, for the treatment of central precocity, by suppressing gonadotropin and estradiol secretion in three children with true precocious puberty. One month after single dose intramuscular i...
متن کاملThe genes associated with gonadotropin-releasing hormone-dependent precocious puberty
Human puberty is a complex, coordinated biological process with multiple levels of regulations. The timing of puberty varies greatly in children and is influenced by both environmental and genetic factors. The key genes of pubertal onset, KISS1, GPR54, GNRH1 and GNRHR, may be major causal factors underlying gonadotropin-releasing hormone-dependent precocious puberty (GDPP). Two gain-of-function...
متن کاملFinal height after gonadotropin-releasing hormone agonists with or without growth hormone in Korean girls with central precocious puberty and early puberty
Results The mean age at the start of treatment was 8.11 ± 0.70 years in group 1, 8.98 ± 0.38 years in group 2 and 9.46 ± 0.46 years in group 3, respectively. The mean predicted adult height (PAH) SDS at the start of treatment was -1.29 ± 1.16 in group 1, -1.14 ± 0.88 in group 2 and -1.87 ± 1.09 in group 3, respectively. Rate of growth during treatment with GnRHa combined with GH was higher sign...
متن کاملTreatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot.
The gonadotropin releasing hormone (GnRH) secreting hypothalamic hamartoma (HH) is a congenital malformation consisting of a heterotopic mass of nervous tissue that contains GnRH neurosecretory neurons attached to the tuber cinereum or the floor of the third ventricle. HH is a well recognised cause of gonadotropin dependent precocious puberty (GDPP). Long term data are presented on eight childr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Transgender Health
سال: 2021
ISSN: 2688-4887,2380-193X
DOI: 10.1089/trgh.2020.0007